2. Search Result
Search Result
Results for "

Vitronectin

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Peptides

1

Inhibitory Antibodies

1

Natural
Products

6

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2452
    Vitronectin (367-378)

    		Integrin Cancer
    Vitronectin (367-378) is a peptide corresponding to residues 367-378 of Vitronectin. Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis .
    Vitronectin (367-378)
  • HY-16141
    Cilengitide
    Maximum Cited Publications
    46 Publications Verification

    EMD 121974

    		 Integrin Autophagy Apoptosis STAT PD-1/PD-L1 Cancer
    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
    Cilengitide
  • HY-P9934
    Abciximab

    C7E3

    		 Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
    Abciximab
  • HY-P1187
    HSDVHK-NH2

    		Integrin Cancer
    HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM) .
    HSDVHK-NH2
  • HY-P1741
    Fibrinogen-Binding Peptide
    1 Publications Verification

    		 Thrombin Cardiovascular Disease
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide
  • HY-P1741A
    Fibrinogen-Binding Peptide TFA
    1 Publications Verification

    		 Integrin Cardiovascular Disease
    Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide TFA
  • HY-N6737
    Aureothricin

    		Bacterial Antibiotic Infection
    Aureothricin is a dithiolopyrrolone (DTP) antibiotic first isolated from Streptomyces and exhibits relatively broad-spectrum antibiotic activity. Aureothricin can inhibit adhesion of human umbilical vein endothelial cells (HUVECs) to vitronectin .
    Aureothricin
  • HY-P2913
    Vitronectin

    		Biochemical Assay Reagents Cancer
    Vitronectin is a multifunctional glycoprotein present in blood and in the extracellular matrix. Vitronectin binds glycosaminoglycans, collagen, plasminogen and the urokinase-receptor. Vitronectin also stabilizes the inhibitory conformation of plasminogen activation inhibitor-1 (PAI-1). Vitronectin can be used for researching wound healing and in tumorprogression .
    Vitronectin
  • HY-117133
    Nesvategrast

    SF0166

    		 Integrin Metabolic Disease
    Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model .
    Nesvategrast
  • HY-P1187A
    HSDVHK-NH2 TFA

    		Integrin Cancer
    HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM) .
    HSDVHK-NH2 TFA
  • HY-125053A
    Batifiban TFA

    		Glycoprotein VI Cardiovascular Disease
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
    Batifiban TFA
  • HY-125053
    Batifiban

    		Integrin Cardiovascular Disease
    Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
    Batifiban
  • HY-120516
    CDE-096

    		PAI-1 Cardiovascular Disease
    CDE-096 is a potent inhibitor of PAI-1. CDE-096 prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively) and is active against glycosylated PAI-1, as well as PAI-1 derived from several species (IC50=19, 22 and 18 nM for murine, rat, and Porcine PAI-1, respectively) .
    CDE-096

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: